{"id":449951,"date":"2021-03-03T16:03:15","date_gmt":"2021-03-03T21:03:15","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=449951"},"modified":"2021-03-03T16:03:15","modified_gmt":"2021-03-03T21:03:15","slug":"amgen-announces-2021-second-quarter-dividend","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-announces-2021-second-quarter-dividend\/","title":{"rendered":"Amgen Announces 2021 Second Quarter Dividend"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">THOUSAND OAKS, Calif.<\/span>, <span class=\"xn-chron\">March 3, 2021<\/span> \/PRNewswire\/ &#8212; Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a <span class=\"xn-money\">$1.76<\/span> per share dividend for the second quarter of 2021. The dividend will be paid on <span class=\"xn-chron\">June 8, 2021<\/span>, to all stockholders of record as of the close of business on <span class=\"xn-chron\">May 17, 2021<\/span>.<\/p>\n<p>\n        <b>About Amgen<\/b><br \/>\n        <b>\u00a0<\/b><br \/>\n        <br \/>Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.\u00a0 <\/p>\n<p>Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people&#8217;s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world&#8217;s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.\u00a0 <\/p>\n<p>For more information, visit\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3085809-1&amp;h=2544340553&amp;u=http%3A%2F%2Fwww.amgen.com%2F&amp;a=www.amgen.com\" rel=\"nofollow noopener noreferrer\">www.amgen.com<\/a>\u00a0and follow us on\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3085809-1&amp;h=3445665142&amp;u=http%3A%2F%2Fwww.twitter.com%2Famgen&amp;a=www.twitter.com%2Famgen\" rel=\"nofollow noopener noreferrer\">www.twitter.com\/amgen<\/a>.\u00a0\u00a0<\/p>\n<p>\n        <b>Amgen Forward-Looking Statements<\/b><br \/>\n        <br \/>This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits\u00a0 and\u00a0 synergies\u00a0 of collaborations,\u00a0 or\u00a0 potential\u00a0 collaborations,\u00a0 with\u00a0 any\u00a0 other\u00a0 company,\u00a0 including BeiGene,\u00a0 Ltd. or any collaboration to\u00a0 manufacture therapeutic antibodies against\u00a0 COVID-19,\u00a0 or the Otezla\u00ae (apremilast) acquisition (including\u00a0 anticipated\u00a0 Otezla\u00a0 sales growth\u00a0 and\u00a0 the\u00a0 timing\u00a0 of\u00a0 non-GAAP EPS\u00a0 accretion),\u00a0 as\u00a0 well\u00a0 as estimates\u00a0 of\u00a0 revenues,\u00a0 operating\u00a0 margins,\u00a0 capital expenditures,\u00a0 cash,\u00a0 other financial metrics, expected legal,\u00a0 arbitration, political, regulatory\u00a0 or clinical results or practices, customer and prescriber\u00a0 patterns\u00a0 or\u00a0 practices,\u00a0 reimbursement\u00a0 activities\u00a0 and\u00a0 outcomes,\u00a0 effects\u00a0 of\u00a0 pandemics or other widespread health problems such as the ongoing COVID-19 pandemic on our business, outcomes, progress,\u00a0 or\u00a0 effects\u00a0 relating\u00a0 to\u00a0 studies\u00a0 of\u00a0 Otezla\u00a0 as\u00a0 a\u00a0 potential\u00a0 treatment\u00a0 for\u00a0 COVID-19, and\u00a0 other\u00a0 such estimates\u00a0 and\u00a0 results. Forward-looking\u00a0 statements\u00a0 involve\u00a0 significant risks\u00a0 and\u00a0 uncertainties,\u00a0 including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to\u00a0 update\u00a0 any\u00a0 forward-looking\u00a0 statements\u00a0 contained\u00a0 in\u00a0 this\u00a0 document\u00a0 as\u00a0 a\u00a0 result\u00a0 of\u00a0 new\u00a0 information, future events or otherwise.<\/p>\n<p>No\u00a0 forward-looking\u00a0 statement can\u00a0 be\u00a0 guaranteed\u00a0 and\u00a0 actual\u00a0 results\u00a0 may\u00a0 differ materially\u00a0 from\u00a0 those\u00a0 we project. Our results may be affected by our ability to successfully market both new and existing products domestically\u00a0 and\u00a0 internationally,\u00a0 clinical\u00a0 and\u00a0 regulatory\u00a0 developments\u00a0 involving\u00a0 current\u00a0 and\u00a0 future products,\u00a0\u00a0 sales\u00a0\u00a0 growth\u00a0\u00a0 of recently\u00a0\u00a0 launched\u00a0\u00a0 products,\u00a0\u00a0 competition\u00a0\u00a0 from other\u00a0\u00a0 products\u00a0\u00a0 including biosimilars,\u00a0 difficulties\u00a0 or\u00a0 delays in\u00a0 manufacturing\u00a0 our\u00a0 products\u00a0 and\u00a0 global\u00a0 economic\u00a0 conditions. In addition,\u00a0 sales\u00a0 of\u00a0 our\u00a0 products\u00a0 are\u00a0 affected\u00a0 by\u00a0 pricing\u00a0 pressure,\u00a0 political\u00a0 and\u00a0 public scrutiny\u00a0 and reimbursement policies\u00a0 imposed by\u00a0 third-party\u00a0 payers,\u00a0 including\u00a0 governments,\u00a0 private\u00a0 insurance\u00a0 plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic\u00a0 and\u00a0 international\u00a0 trends\u00a0 toward\u00a0 managed\u00a0 care\u00a0 and\u00a0 healthcare\u00a0 cost\u00a0 containment. Furthermore, our\u00a0 research,\u00a0 testing,\u00a0 pricing,\u00a0 marketing\u00a0 and\u00a0 other\u00a0 operations\u00a0 are\u00a0 subject\u00a0 to\u00a0 extensive\u00a0 regulation\u00a0 by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems\u00a0 with\u00a0 our\u00a0 products,\u00a0 including\u00a0 our\u00a0 devices, after\u00a0 they\u00a0 are\u00a0 on\u00a0 the\u00a0 market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our\u00a0 business\u00a0 may\u00a0 be\u00a0 impacted\u00a0 by the\u00a0 adoption\u00a0 of\u00a0 new\u00a0 tax legislation\u00a0 or\u00a0 exposure\u00a0 to\u00a0 additional\u00a0 tax liabilities. If\u00a0 we\u00a0 fail\u00a0 to\u00a0 meet\u00a0 the\u00a0 compliance obligations\u00a0 in\u00a0 the\u00a0 corporate\u00a0 integrity\u00a0 agreement\u00a0 between\u00a0 us and\u00a0 the\u00a0 U.S.\u00a0 government,\u00a0 we\u00a0 could\u00a0 become\u00a0 subject\u00a0 to\u00a0 significant\u00a0 sanctions.\u00a0 Further, while we\u00a0 routinely obtain\u00a0 patents\u00a0 for\u00a0 our \u00a0products\u00a0 and\u00a0 technology,\u00a0 the\u00a0 protection\u00a0 offered\u00a0 by\u00a0 our\u00a0 patents and\u00a0 patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in\u00a0 present\u00a0 and\u00a0 future\u00a0 intellectual property\u00a0 litigation. We perform\u00a0 a\u00a0 substantial\u00a0 amount of\u00a0 our\u00a0 commercial manufacturing activities at a few key facilities, including in <span class=\"xn-location\">Puerto Rico<\/span>, and also depend on third parties for\u00a0 a\u00a0 portion\u00a0 of\u00a0 our\u00a0 manufacturing\u00a0 activities,\u00a0 and\u00a0 limits\u00a0 on supply\u00a0 may\u00a0 constrain\u00a0 sales\u00a0 of\u00a0 certain of\u00a0 our current\u00a0 products\u00a0 and product\u00a0 candidate\u00a0 development.\u00a0 An\u00a0 outbreak\u00a0 of\u00a0 disease or\u00a0 similar\u00a0 public\u00a0 health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease,\u00a0 could\u00a0 have a significant\u00a0 adverse\u00a0 effect on\u00a0 the\u00a0 supply\u00a0 of materials\u00a0 for\u00a0 our\u00a0 manufacturing activities,\u00a0 the\u00a0 distribution of\u00a0 our\u00a0 products,\u00a0 the\u00a0 commercialization\u00a0 of\u00a0 our\u00a0 product\u00a0 candidates,\u00a0 and\u00a0 our clinical\u00a0 trial\u00a0 operations,\u00a0 and\u00a0 any\u00a0 such\u00a0 events\u00a0 may\u00a0 have\u00a0 a\u00a0 material\u00a0 adverse effect\u00a0 on\u00a0 our\u00a0 product development,\u00a0 product\u00a0 sales,\u00a0 business\u00a0 and\u00a0 results\u00a0 of\u00a0 operations. We\u00a0 rely\u00a0 on\u00a0 collaborations with\u00a0 third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our\u00a0 marketed\u00a0 products\u00a0 as\u00a0 well\u00a0 as for\u00a0 the\u00a0 discovery\u00a0 and\u00a0 development\u00a0 of\u00a0 new\u00a0 products.\u00a0 Discovery\u00a0 or identification\u00a0 of\u00a0 new\u00a0 product\u00a0 candidates or\u00a0 development\u00a0 of\u00a0 new\u00a0 indications\u00a0 for\u00a0 existing\u00a0 products cannot be\u00a0 guaranteed\u00a0 and\u00a0 movement from\u00a0 concept\u00a0 to\u00a0 product\u00a0 is\u00a0 uncertain;\u00a0 consequently,\u00a0 there\u00a0 can\u00a0 be\u00a0 no guarantee\u00a0 that\u00a0 any\u00a0 particular\u00a0 product\u00a0 candidate or\u00a0 development\u00a0 of a new\u00a0 indication\u00a0 for an existing product will\u00a0 be\u00a0 successful\u00a0 and\u00a0 become\u00a0 a\u00a0 commercial\u00a0 product.\u00a0 Further,\u00a0 some\u00a0 raw\u00a0 materials, medical devices\u00a0 and\u00a0 component\u00a0 parts\u00a0 for\u00a0 our\u00a0 products\u00a0 are\u00a0 supplied by\u00a0 sole\u00a0 third-party\u00a0 suppliers. Certain\u00a0 of\u00a0 our distributors,\u00a0 customers\u00a0 and\u00a0 payers\u00a0 have\u00a0 substantial\u00a0 purchasing\u00a0 leverage\u00a0 in\u00a0 their\u00a0 dealings\u00a0 with\u00a0 us. The discovery\u00a0 of\u00a0 significant problems\u00a0 with\u00a0 a product\u00a0 similar\u00a0 to\u00a0 one\u00a0 of our products\u00a0 that\u00a0 implicate\u00a0 an\u00a0 entire class\u00a0 of\u00a0 products\u00a0 could\u00a0 have\u00a0 a\u00a0 material\u00a0 adverse\u00a0 effect\u00a0 on\u00a0 sales\u00a0 of\u00a0 the\u00a0 affected\u00a0 products\u00a0 and\u00a0 on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and\u00a0 to\u00a0 integrate\u00a0 the\u00a0 operations of\u00a0 companies or\u00a0 to\u00a0 support\u00a0 the\u00a0 products\u00a0 or\u00a0 technology we have acquired,\u00a0 may\u00a0 not\u00a0 be\u00a0 successful. A\u00a0 breakdown,\u00a0 cyberattack\u00a0 or\u00a0 information\u00a0 security\u00a0 breach could compromise\u00a0 the\u00a0 confidentiality,\u00a0 integrity\u00a0 and\u00a0 availability\u00a0 of\u00a0 our\u00a0 systems\u00a0 and\u00a0 our\u00a0 data. Our\u00a0 stock\u00a0 price\u00a0 is volatile\u00a0 and\u00a0 may be\u00a0 affected\u00a0 by\u00a0 a\u00a0 number\u00a0 of\u00a0 events. Global\u00a0 economic\u00a0 conditions may\u00a0 magnify certain risks\u00a0 that\u00a0 affect\u00a0 our\u00a0 business. Our\u00a0 business\u00a0 performance\u00a0 could\u00a0 affect\u00a0 or limit the\u00a0 ability\u00a0 of\u00a0 our Board\u00a0 of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.<\/p>\n<p>CONTACT: Amgen, Thousand Oaks\u00a0<br \/><span class=\"xn-person\">Megan Fox<\/span>, 805-447-1423 (media)<br \/><span class=\"xn-person\">Trish Rowland<\/span>, 805-447-5631(media)\u00a0<br \/><span class=\"xn-person\">Arvind Sood<\/span>, 805-447-1060 (investors)\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1863\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/152881\/amgen_logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/152881\/amgen_logo.jpg\" title=\"Amgen Logo. (PRNewsFoto\/Amgen) (PRNewsFoto\/)\" alt=\"Amgen Logo. (PRNewsFoto\/Amgen) (PRNewsFoto\/)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA98187&amp;sd=2021-03-03\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/amgen-announces-2021-second-quarter-dividend-301240017.html\">http:\/\/www.prnewswire.com\/news-releases\/amgen-announces-2021-second-quarter-dividend-301240017.html<\/a><\/p>\n<p>SOURCE  Amgen<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA98187&amp;Transmission_Id=202103031600PR_NEWS_USPR_____LA98187&amp;DateId=20210303\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire THOUSAND OAKS, Calif., March 3, 2021 \/PRNewswire\/ &#8212; Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.76 per share dividend for the second quarter of 2021. The dividend will be paid on June 8, 2021, to all stockholders of record as of the close of business on May 17, 2021. About Amgen \u00a0 Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.\u00a0 Amgen focuses on areas of high unmet medical need and leverages its expertise to strive &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-announces-2021-second-quarter-dividend\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Amgen Announces 2021 Second Quarter Dividend&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-449951","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Amgen Announces 2021 Second Quarter Dividend - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-announces-2021-second-quarter-dividend\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amgen Announces 2021 Second Quarter Dividend - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire THOUSAND OAKS, Calif., March 3, 2021 \/PRNewswire\/ &#8212; Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.76 per share dividend for the second quarter of 2021. The dividend will be paid on June 8, 2021, to all stockholders of record as of the close of business on May 17, 2021. About Amgen \u00a0 Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.\u00a0 Amgen focuses on areas of high unmet medical need and leverages its expertise to strive &hellip; Continue reading &quot;Amgen Announces 2021 Second Quarter Dividend&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-announces-2021-second-quarter-dividend\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-03T21:03:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/152881\/amgen_logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amgen-announces-2021-second-quarter-dividend\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amgen-announces-2021-second-quarter-dividend\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Amgen Announces 2021 Second Quarter Dividend\",\"datePublished\":\"2021-03-03T21:03:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amgen-announces-2021-second-quarter-dividend\\\/\"},\"wordCount\":1164,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amgen-announces-2021-second-quarter-dividend\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/152881\\\/amgen_logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amgen-announces-2021-second-quarter-dividend\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amgen-announces-2021-second-quarter-dividend\\\/\",\"name\":\"Amgen Announces 2021 Second Quarter Dividend - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amgen-announces-2021-second-quarter-dividend\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amgen-announces-2021-second-quarter-dividend\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/152881\\\/amgen_logo.jpg\",\"datePublished\":\"2021-03-03T21:03:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amgen-announces-2021-second-quarter-dividend\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amgen-announces-2021-second-quarter-dividend\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amgen-announces-2021-second-quarter-dividend\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/152881\\\/amgen_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/152881\\\/amgen_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amgen-announces-2021-second-quarter-dividend\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amgen Announces 2021 Second Quarter Dividend\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amgen Announces 2021 Second Quarter Dividend - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-announces-2021-second-quarter-dividend\/","og_locale":"en_US","og_type":"article","og_title":"Amgen Announces 2021 Second Quarter Dividend - Market Newsdesk","og_description":"PR Newswire THOUSAND OAKS, Calif., March 3, 2021 \/PRNewswire\/ &#8212; Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.76 per share dividend for the second quarter of 2021. The dividend will be paid on June 8, 2021, to all stockholders of record as of the close of business on May 17, 2021. About Amgen \u00a0 Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.\u00a0 Amgen focuses on areas of high unmet medical need and leverages its expertise to strive &hellip; Continue reading \"Amgen Announces 2021 Second Quarter Dividend\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-announces-2021-second-quarter-dividend\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-03T21:03:15+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/152881\/amgen_logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-announces-2021-second-quarter-dividend\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-announces-2021-second-quarter-dividend\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Amgen Announces 2021 Second Quarter Dividend","datePublished":"2021-03-03T21:03:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-announces-2021-second-quarter-dividend\/"},"wordCount":1164,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-announces-2021-second-quarter-dividend\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/152881\/amgen_logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-announces-2021-second-quarter-dividend\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-announces-2021-second-quarter-dividend\/","name":"Amgen Announces 2021 Second Quarter Dividend - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-announces-2021-second-quarter-dividend\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-announces-2021-second-quarter-dividend\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/152881\/amgen_logo.jpg","datePublished":"2021-03-03T21:03:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-announces-2021-second-quarter-dividend\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/amgen-announces-2021-second-quarter-dividend\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-announces-2021-second-quarter-dividend\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/152881\/amgen_logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/152881\/amgen_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amgen-announces-2021-second-quarter-dividend\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Amgen Announces 2021 Second Quarter Dividend"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/449951","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=449951"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/449951\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=449951"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=449951"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=449951"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}